Ischemia - Pipeline Review, H2 2015 Now Available at

iData Insights
Ischemia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Ischemia - Pipeline Review, H2
2015, provides an overview of the Ischemias therapeutic pipeline. This report provides comprehensive
information on the therapeutic development for Ischemia, complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic development for Ischemia and special
features on late-stage and discontinued projects. Global Markets Directs report features investigational
drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together by Global Markets
Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a
stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Ischemia - The report reviews key pipeline
products under drug profile section which includes, product description, MoA and R&D brief, licensing
and collaboration details & other developmental activities - The report reviews key players involved in
the therapeutics development for Ischemia and enlists all their major and minor projects - The report
summarizes all the dormant and discontinued pipeline projects - A review of the Ischemia products
under development by companies and universities/research institutes based on information derived
from company and industry-specific sources - Pipeline products coverage based on various stages of
development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment
of monotherapy and combination therapy pipeline projects - Coverage of the Ischemia pipeline on the
basis of target, MoA, route of administration and molecule type - Latest news and deals relating related
to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Ischemia Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of
Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand business potential and
scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline.
1

with TOC
@ http://www.idatainsights.com/reports-landing-page.php?id=173358/ischemiapipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173358/ischemia-pipeline-review-h2-2015

Table of Contents

Introduction 8
Global Markets Direct Report Coverage 8
Ischemia Overview 9
Therapeutics Development 10
Pipeline Products for Ischemia - Overview 10
Pipeline Products for Ischemia - Comparative Analysis 11
Ischemia - Therapeutics under Development by Companies 12
Ischemia - Therapeutics under Investigation by Universities/Institutes 16
Ischemia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Ischemia - Products under Development by Companies 20
Ischemia - Products under Investigation by Universities/Institutes 24
Ischemia - Companies Involved in Therapeutics Development 25
Alize Pharma SAS 25
Amyndas Pharmaceuticals LLC 26
AnGes MG, Inc. 27
Apceth GmbH & Co. KG 28
Athersys, Inc. 29
2

Baxalta Incorporated 30
Caladrius Biosciences, Inc. 31
Cellmid Limited 32
CoDa Therapeutics, Inc. 33
CohBar, Inc. 34
Cynata Therapeutics Limited 35
DNAVEC Corporation 36
GlaxoSmithKline Plc 37
Hemostemix Ltd 38
IntelliCell BioSciences Inc. 39
Juventas Therapeutics, Inc. 40
Kasiak Research Private Limited 41
Lixte Biotechnology Holdings, Inc. 42
Mesoblast Limited 43
Miltenyi Biotec GmbH 44
Mirrx Therapeutics A/S 45
Multi Gene Vascular Systems Ltd 46
NoNO, Inc. 47
Nyken BV 48
Pathfinder Cell Therapy, Inc. 49
Pharmicell Co., Ltd. 50
Pluristem Therapeutics Inc. 51
Protagenic Therapeutics Inc. 52

ReNeuron Group Plc 53

Sihuan Pharmaceutical Holdings Group Ltd. 54
Stempeutics Research Private Limited 55
Targazyme, Inc. 56
Taxus Cardium Pharmaceuticals Group Inc. 57
TikoMed AB 58
U.S. Stem Cell, Inc. 59
Vericel Corporation 60
ViroMed Co., Ltd. 61
Ischemia - Therapeutics Assessment 62
Assessment by Monotherapy Products 62
Assessment by Target 63
Assessment by Mechanism of Action 66
Assessment by Route of Administration 68
Assessment by Molecule Type 70
Drug Profiles 72
AB-002 - Drug Profile 72
ACP-01 - Drug Profile 74
AdipoCell - Drug Profile 76
Alda-1 - Drug Profile 78
Alecmestencel-T - Drug Profile 79
alferminogene tadenovec - Drug Profile 80
AntimiR-199a - Drug Profile 82
ASCT-01 - Drug Profile 83
4

Autologous Vascular Cells Therapy - Drug Profile 84

AZP-531 - Drug Profile 85
beperminogene perplasmid - Drug Profile 87
bucillamine - Drug Profile 92
CD-52 - Drug Profile 93
Cell Therapy for Critical Limb Ischemia - Drug Profile 94
Cell Therapy for Ischemia - Drug Profile 95
Cell Therapy for Ischemia - Drug Profile 96
Cellgram for Severe Lower Limb Ischemia - Drug Profile 97
Cinepazide Mesylate - Drug Profile 98
CLBS-12 - Drug Profile 99
CMK-103 - Drug Profile 100
daprodustat - Drug Profile 101
DVC1-0101 - Drug Profile 103
EP-80317 - Drug Profile 105
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 106
Humanin - Drug Profile 107
ixmyelocel-T - Drug Profile 109
JVS-100 - Drug Profile 112
JVS-200 - Drug Profile 114
LB-100 - Drug Profile 115
LB-102 - Drug Profile 117
MicroRNA for Ischemia - Drug Profile 119

MPC-25IC - Drug Profile 120

MultiGeneAngio - Drug Profile 121
MultiStem - Drug Profile 123
NYK-1112 - Drug Profile 127
Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease - Drug Profile 128
Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders - Drug Profile 129
Pathfinder Cells - Drug Profile 130
Peptagon - Drug Profile 132
PLX-PAD - Drug Profile 133
PMC-6 - Drug Profile 137
Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 138
PT-00114 - Drug Profile 139
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug
Profile 140
Recombinant Protein for Critical Limb Ischemia - Drug Profile 141
Recombinant Protein for Ischemia - Drug Profile 142
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile 143
Refacell-CLI - Drug Profile 144
Rejuveinix - Drug Profile 145
ReN-009 - Drug Profile 146
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion
Injury - Drug Profile 147
Small Molecules for Ischemia and Reperfusion Injury - Drug Profile 148
Small Molecules for Renal Failure and Renal Ischemia - Drug Profile 149
Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 150
6

Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 151
Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 152
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile 153
Stem Cell Therapy for Cardiovascular Disease - Drug Profile 154
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 156
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile 158
Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile 159
Stempeucel - Drug Profile 160
Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile 163
TM-700 - Drug Profile 164
TZ-101 - Drug Profile 165
VM-202 - Drug Profile 167
Ischemia - Recent Pipeline Updates 169
Ischemia - Dormant Projects 206
Ischemia - Discontinued Products 212
Ischemia - Product Development Milestones 213
Featured News & Press Releases 213
Appendix 218
Methodology 218
Coverage 218
Secondary Research 218
Primary Research 218
Expert Panel Validation 218

Contact Us 218
Disclaimer 219"

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173358/ischemia-pipelinereview-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects